A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms

Tarinee Rungjirajittranon, Weerapat Owattanapanich, Patompong Ungprasert, Noppadol Siritanaratkul and Theera Ruchutrakool

Abstract

Background: Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most patients with MPN are asymptomatic at diagnosis although some of them suffer from constitutional symptoms. Thrombosis and bleeding can also be one of the initial manifestations although the reported prevalence varied considerably across the studies. This systematic review and meta-analysis was conducted with the aims to better understand the prevalence and characteristics of thrombosis and bleeding among patients with newly-diagnosed MPN.

Methods: Using a search strategy that included the terms for myeloproliferative neoplasms, thrombosis, and bleeding, two investigators independently searched for published articles indexed in the MEDLINE and EMBASE databases from inception to August 2018. The pooled prevalence was calculated using the DerSimonian–Laird random-effects model with a double arcsine transformation.

Results: A total of 29 cohort studies (8 prospective and 21 retrospective) with 13,436 patients with MPN were included into this meta-analysis. At diagnosis, the pooled prevalence of overall thrombosis among patients with MPN was 20.0% (95% CI, 16.6–23.8%; I² 96%), with the pooled prevalence of arterial thrombosis of 16.2% (95% CI, 13.0–20.0%; I² 95%) and the pooled prevalence of venous thrombosis of 6.2% (95% CI, 4.9–7.8%; I² 89%). Common thrombotic events included cerebrovascular disease/transient ischemic attack, coronary heart disease, and deep venous thrombosis. The pooled prevalence of hemorrhagic complications among patients who were newly diagnosed with MPN patients was 6.2% (95% CI, 5.0–7.8%; I² 85%). Common sites of bleeding included gastrointestinal, mucosal, and cutaneous bleeding.

Conclusions: Thrombosis and bleeding are common initial manifestations of MPN. Investigations for MPN should be considered for patients who present with unexplained thrombosis or abnormal bleeding.

Keywords: Myeloproliferative neoplasms, Polycythemia vera, Essential thrombocythemia, Primary myelofibrosis, Prevalence, Thrombosis, Bleeding, Hemorrhage
**Background**
Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms (MPNs) are a heterogenous group of hematopoietic stem cell clonal diseases, of which the main subtypes are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) [1, 2]. More than half of the patients are asymptomatic at diagnosis although some of them suffer from weight loss, fatigue, fever, pruritus, and early satiety. Thrombosis and bleeding can also be ones of the initial manifestations that eventually lead to the diagnosis of MPN [3, 4].

Thrombosis in patients with MPN could manifest as mild microcirculatory disturbance or as major arterial and venous thrombotic events such as ischemic stroke, myocardial infarction, peripheral arterial disease, and deep vein thrombosis [5]. Similarly, bleeding in these patients can be a minor one or could manifest as major internal organ hemorrhage [6]. The reported prevalence of thrombosis and bleeding among patients who were newly diagnosed with MPN varied considerably across the studies [7–35]. As one of the aims of the treatments of MPN is to decrease the risk of thrombosis and some prescribed medications, such as aspirin, can increase the risk of bleeding, knowing the baseline prevalence of thrombosis and bleeding would be of clinical importance for clinicians who need to balance the risk between these two opposite complications. The current systematic review and meta-analysis was conducted with the aims to better understand the prevalence and characteristics of thrombosis and bleeding among patients with newly-diagnosed MPN by comprehensively identifying all available studies and summarizing their results together.

**Methods**

**Data sources and searches**
Using a search strategy that included the terms for myeloproliferative neoplasms, thrombosis, and bleeding, two investigators (T.R.1 and W.O.) independently searched for published articles indexed in the MEDLINE and EMBASE databases from inception to August 2018. The search strategy is available as Additional file 1. In addition, the references of the included studies were also manually reviewed to identify additional eligible studies. This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, which is available as Additional file 2 [36].

**Selection criteria and data extraction**
To be eligible for inclusion into the meta-analysis, first, the study needed to consist of at least one cohort of patients who were newly diagnosed with Philadelphia negative MPNs (PV, ET, or PMF). Then, the study needed to report the overall prevalence of thrombosis and/or bleeding at diagnosis of that cohort. The secondary outcomes of interest, including prevalence of thrombosis for each MPN subtype, prevalence of thrombosis at each location, prevalence of bleeding for each MPN subtype, and prevalence of bleeding at each location, were also collected for pooled analysis but were not part of the inclusion criteria. Both investigators evaluated all studies independently. If different decisions regarding the eligibility of a study were made, the study in question was jointly reviewed by the two investigators and the final determination was reached by consensus.

**Statistical analysis**
Comprehensive Meta-Analysis program, version 2.2 (Biostat, Englewood, NJ, USA) was used to analyze all data. The same two authors (T.R.1 and W.O.) extracted and tabulated all data from each eligible study using a standardized data extraction form. The pooled rates and 95% confidence intervals (CI) of the overall prevalence of thrombosis at diagnosis, overall prevalence of bleeding at diagnosis, prevalence of thrombosis at each location, prevalence of bleeding for each MPN subtype, and prevalence of bleeding at each location, were calculated using the DerSimonian–Laird random-effects model with a double arcsine transformation [37]. The random-effects model was utilized as opposed to a fixed-effects model as the between-study heterogeneity was suspected to be high due to the difference in background populations between studies. The heterogeneity was calculated using Cochran’s Q test and the I² statistic. The I² statistic quantifies the proportion of total variation across studies; the I² values were classified as follows: an I² of 0–25% indicated insignificant heterogeneity; 26–50%, low heterogeneity; 51–75%, moderate heterogeneity; and greater than 75%, high heterogeneity [38].

**Results**
A total of 6177 articles (2672 from MEDLINE and 3505 from EMBASE) were identified using the aforementioned search strategy. A total of 2306 articles were duplication between the databases, which were removed using EndNote X8 software, leaving 3871 articles for the first round of review (review of title and abstract). After the first round of review, 3754 articles were excluded because they clearly did not meet the pre-specified inclusion criteria based on type of article, study design, and study participants. A full-text review of the remaining 117 articles was undertaken and 88 articles were found to be ineligible for the meta-analysis (16 articles were reviews, meta-analysis or commentaries; 3 articles did not recruit patients with MPNs; and 69 articles did not...
report our outcome of interest). Finally, 29 cohort studies (8 prospective studies and 21 retrospective studies) were included in the meta-analysis [7–35]. The literature review and identification process are summarized as Fig. 1.

Baseline patient characteristics
A total of 13,436 patients who were newly diagnosed with MPN from 29 studies were included in this meta-analysis. ET was the most common subtype of MPN among patients analyzed in this meta-analysis (49.2%), followed by PV (34.7%), and PMF (14.4%). There was a slight overall female predominance (52.4%) while the median age of participants ranged from 42 to 76 years across the studies. The prevalence of thrombosis was reported by 26 studies while the prevalence of bleeding was reported by 21 studies. Table 1 describes the characteristics and participants of the included studies. The data on managements and clinical outcomes of participants in these studies are described in Additional file 3: Table S1.

Prevalence of thrombosis at diagnosis of MPN
At diagnosis, the pooled prevalence of overall thrombosis (either arterial or venous) among patients with MPN was 20.0% (95% CI, 16.6–23.8%; I² 96%; Fig. 2) [7–18, 20–23, 25–32, 34, 35]. The pooled prevalence for each MPN subtype was as followed; PV 28.6% (95% CI, 22.0–36.3%; I² 95%) [10, 12, 14, 18, 19, 26, 28, 29, 31, 32], ET 20.7% (95% CI, 16.6–25.5%; I² 93%) [7–11, 13, 16–18, 22, 25, 26, 28, 29, 31, 32, 34], and PMF 9.5% (95% CI, 5.0–17.4%; I² 94%) [10, 20, 21, 23, 26, 28, 29, 32] (Fig. 3). The pooled prevalence of arterial thrombosis was 16.2% (95% CI, 13.0–20.0%; I² 95%) [7–14, 17–23, 26–29, 31, 32, 34, 35] while the pooled prevalence of venous thrombosis was 6.2% (95% CI, 4.9–7.8%; I² 89%) (Fig. 4) [7–14, 17–23, 26, 28, 29, 31, 32, 34, 35].

Sites of arterial thrombosis
The pooled prevalence of arterial thrombosis at diagnosis of MPN for each specific site was as followed; cerebrovascular disease 7.4% (95% CI, 5.0–10.8%; I² 90%) [7–9, 11, 13, 14, 19, 21, 25–27, 29], transient ischemic attack of 3.5% (95% CI, 1.9–6.4%; I² 91%) [8, 9, 11, 13, 19, 21, 25–27, 35], coronary heart disease 6.1% (95% CI, 5.1–7.4%; I² 73%) [7–14, 17, 19–22, 25–29, 31, 35], and peripheral arterial disease 3.3% (95% CI, 2.2–4.8%; I² 87%) [7–9, 11, 13, 14, 17, 19–22, 26, 28, 31]. The forest plots of each arterial thrombotic event are provided as Additional file 4.

Sites of venous thrombosis
The pooled prevalence of venous thrombosis at diagnosis of MPN for each specific site was as followed; deep vein thrombosis 3.4% (95% CI, 2.0–5.6%; I² 85%) [7–9, 14, 18, 19, 28, 29, 35], splanchic vein thrombosis
### Table 1 Baseline patient characteristics of the included studies

| References | No. (M/F) | Median age (years, range) | No. of PV | No. of ET | No. of PMF | Thrombotic outcome | Bleeding outcome | Study period | Type |
|------------|-----------|---------------------------|-----------|-----------|------------|-------------------|-----------------|-------------|------|
| Fenaux 1990 [7] | 147/60 | 60 (18–83) | – | 147 | – | Yes (A + V) | Yes | 1970–1987 | R |
| Colombi 1991 [8] | 103/44 | 59 (9–88) | – | 103 | – | Yes (A + V) | Yes | 1975–1990 | R |
| Besses 1999 [9] | 148/53 | 60.5 (11–85) | – | 148 | – | Yes (A + V) | Yes | 1979–1994 | R |
| Manoharan 1999 [10] | 61 | PV: 10/10 ET: 10/20 PMF: 5/6 | PV: 76 (54–84) ET: 71 (25–88) PMF: 74 (31–84) | 20 | 30 | 11 | Yes (A + V) | No | 1993–1997 | P |
| Jensen 2000 [11] | 96/27 | 67 (18–87) | – | 96 | – | Yes (A + V) | Yes | 1977–1998 | R |
| Passamonti 2000 [12] | 163/98 | 57 (30–82) | 163 | – | – | Yes (A + V) | Yes | 1975–1997 | R |
| Chir 2005 [13] | 231/112 | 65 (18–90) | – | 231 | – | Yes (A + V) | Yes | NR | R |
| Marchioli 2005 [14] | 1638/942 | 60.4 | 1638 | – | – | Yes (A + V) | Yes | NR | P |
| Cervantes 2006 [15] | 155/97 | 65 (17–89) | – | – | 155 | Yes (A + V) | No | 1972–2005 | R |
| Wolanskyj 2006 [16] | 322/104 | 54 (12–88) | – | 322 | – | Yes (A + V) | Yes | 1956–1992 | R |
| Carobbio 2007 [17] | 439/175 | 54 (10–93) | – | – | 439 | Yes (A + V) | No | 1981–2006 | R |
| Vannucchi 2007 [18] | 962/276 | NR | 323 | 639 | – | Yes (A + V) | No | NR | R |
| Bang 2009 [19] | 283/143 | 61 | 120 | NR | NR | Yes (A + V) | Yes | 2006–2007 | P |
| Barbui 2010 [20] | 707/465 | 62 (11–90) | – | – | 707 | Yes (A + V) | No | 1973–2008 | R |
| Elliott 2010 [21] | 205/131 | 62 (28–87) | – | – | 205 | Yes (A + V) | No | 1982–2008 | R |
| Palandri 2011 [22] | 532/205 | 64 (16–95) | – | 532 | – | Yes (A + V) | No | 1978–2008 | R |
| Buxorfer-Ausch 2012 [23] | 264/109 | 57.4 | – | – | 264 | Yes (A + V) | No | NR | P |
| Finazzi 2012 [24] | 1104/70 | ET: 370/521 PMF: 74/106 ET: 55.7 (12.9–91) PMF: 57.4 (20.9–87.7) | – | 891 | 180 | No | Yes | NR | P |
| Angona 2015 [25] | 214/57 | 64 (9–93) | – | 214 | – | Yes (A + V) | No | 1985–2012 | R |
| Embolm 2015 [26] | 612/131 | PV: 131/118 ET: 117/155 PMF: 47/44 ET: 69 PMF: 71 | 249 | 272 | 91 | Yes (A + V) | Yes | 1995–2013 | R |
| Lim 2015 [27] | 102/54 | 64 (24–87) | 33 | 69 | – | Yes (A) | Yes | 2004–2012 | R |
| Duangnapasatit 2015 [28] | 157/46 | PV: 46/22 ET: 32/51 PMF: 4/2 PV: 59.6 (18–88) ET: 61.1 (21–89) PMF: 68.3 (52–78) | 68 | 83 | 6 | Yes (A + V) | Yes | 2003–2013 | R |
| Kaife 2016 [29] | 454/232 | 60 | 142 | 140 | 113 | Yes (A + V) | Yes | NR | P |
| Cercequozzi 2017 [30] | 587/284 | 60 (17–94) | 587 | – | – | Yes (A + V) | No | NR | P |
| Abdulkarim 2017 [31] | 2389/548 | PV: 548/557 ET: 534/750 PV: 69 (17–98) ET: 68 (13–94) | 1105 | 1284 | – | Yes (A + V) | Yes | 2008–2015 | R |
| Soyer 2017 [32] | 708/132 | ET: 151/239 PMF: 56/49 ET: 47.5 (17–86) PMF: 41.5 (17–89) PMF: 69.5 (19–87) | 213 | 390 | 105 | Yes (A + V) | Yes | 1987–2014 | R |
| Bertozzi 2017 [33] | 253/ NR | NR | 124 | 121 | 8 | Yes (A) | Yes | 1978–2016 | R |
| Zhou 2018 [34] | 150/67 | 61 (41–71) | – | – | 150 | Yes (A + V) | No | 2013–2016 | P |
| Hintermaier 2018 [35] | 250/152 | NR | NR | NR | NR | Yes (A + V) | No | 2008–2015 | R |

**Abbreviations:** A Artery, ET Essential thrombocythemia, F Female, M Male, NR Not reported, P Prospectively, PMF Primary myelofibrosis, PV Polycythemia vera, R Retrospectively, V Vein

Prevalence of bleeding at diagnosis of MPN

The pooled prevalence of hemorrhagic complications among patients who were newly diagnosed with MPN patients was 6.2% (95% CI, 5.0–7.8%; I² 85%; Fig. 5) [7–9, 11–14, 16, 18, 19, 24–29, 31–35]. The pooled prevalence for each MPN subtype was as followed;
Fig. 2 Forest plot of pooled prevalence and 95% confidence interval of overall thrombosis in patients with MPN

Study name | Event rate | Lower limit | Upper limit
---|---|---|---
Fenaux 1990 | 0.184 | 0.129 | 0.255
Colombi 1991 | 0.223 | 0.153 | 0.314
Bessis 1999 | 0.331 | 0.260 | 0.411
Manoharan 1999 | 0.246 | 0.154 | 0.369
Jensen 2000 | 0.365 | 0.275 | 0.465
Passamonti 2000 | 0.160 | 0.111 | 0.224
Chin 2005 | 0.130 | 0.092 | 0.180
Marchioi 2005 | 0.386 | 0.363 | 0.410
Gerventes 2006 | 0.039 | 0.017 | 0.083
Wolanskyj 2006 | 0.264 | 0.219 | 0.315
Carobbio 2007 | 0.294 | 0.253 | 0.338
Vannucchi 2007 | 0.183 | 0.160 | 0.209
Barbui 2010 | 0.095 | 0.075 | 0.119
Elliott 2010 | 0.132 | 0.092 | 0.185
Falanga 2011 | 0.169 | 0.140 | 0.203
Busatto-Ausch 2012 | 0.220 | 0.174 | 0.274
Angona 2015 | 0.084 | 0.054 | 0.130
Enblom 2015 | 0.235 | 0.203 | 0.271
Lim 2015 | 0.176 | 0.144 | 0.263
Duangnapasati 2015 | 0.152 | 0.110 | 0.206
Kaffie 2016 | 0.318 | 0.274 | 0.367
Cerqua 2017 | 0.249 | 0.215 | 0.285
Abdurrahman 2017 | 0.359 | 0.340 | 0.379
Soyer 2017 | 0.190 | 0.154 | 0.198
Zhou 2018 | 0.340 | 0.289 | 0.419
Hintermaier 2018 | 0.064 | 0.040 | 0.102
0.200 | 0.166 | 0.238

Fig. 3 Forest plot of pooled prevalence and 95% confidence interval of overall thrombosis of each MPN subtype: a polycythemia vera; (b) essential thrombocythemia; (c) primary myelofibrosis

Study name | Event rate | Lower limit | Upper limit
---|---|---|---
Manoharan 1999 | 0.400 | 0.214 | 0.620
Passamonti 2000 | 0.160 | 0.111 | 0.224
Marchioi 2005 | 0.386 | 0.363 | 0.410
Vannucchi 2007 | 0.192 | 0.153 | 0.239
Biag 2009 | 0.596 | 0.491 | 0.692
Duangnapasati 2015 | 0.324 | 0.223 | 0.443
Enblom 2015 | 0.080 | 0.052 | 0.121
Kaffie 2016 | 0.388 | 0.311 | 0.472
Abdurrahman 2017 | 0.372 | 0.344 | 0.401
Soyer 2017 | 0.207 | 0.157 | 0.266
0.286 | 0.220 | 0.303

Study name | Event rate | Lower limit | Upper limit
---|---|---|---
Manoharan 1999 | 0.033 | 0.008 | 0.122
Barbui 2010 | 0.095 | 0.075 | 0.119
Elliott 2010 | 0.038 | 0.026 | 0.055
Busotto-Ausch 2012 | 0.220 | 0.174 | 0.274
Duangnapasati 2015 | 0.071 | 0.034 | 0.177
Enblom 2015 | 0.044 | 0.017 | 0.111
Kaffie 2016 | 0.312 | 0.232 | 0.405
Soyer 2017 | 0.065 | 0.052 | 0.168
0.095 | 0.050 | 0.174
PMF 8.9% (95% CI, 6.5–12.2%; \(I^2\) 0%) \[24, 28, 29, 32\], ET 7.3% (95% CI, 5.3–10.0%; \(I^2\) 84%) \[7–9, 11, 13, 16, 24, 28, 29, 31, 32, 34\], and PV 6.9% (95% CI, 5.5–8.7%; \(I^2\) 53%) \(\text{(Fig. 6)}\) \[12, 14, 28, 29, 31, 32\].

Prevalence of some specific types of bleeding at the diagnosis of MPN was reported by the included studies. Their pooled prevalence was as followed; mucocutaneous bleeding 2.8% (95% CI, 1.4–5.8%; \(I^2\) 35%) \[11, 19, 28\], gastrointestinal bleeding 2.1% (95% CI, 1.3–3.1%; \(I^2\) 68%) \[7, 8, 11, 13, 24, 26, 28, 29, 31, 35\], epistaxis 1.0% (95% CI, 0.5–2.0%; \(I^2\) 0%) \[8, 11, 26\], and postoperative bleeding 1.1% (95% CI, 0.5–2.1%; \(I^2\) 0%) \[8, 11, 28, 29\]. The forest plots of each specific type of bleeding are provided as Additional file 5.

**Discussion**

The current study is the first systematic review and meta-analysis to evaluate the frequency of thrombotic
and hemorrhagic events as the initial manifestations of MPN. We found the pooled prevalence of thrombosis at diagnosis of MPN of 20% although the prevalence from individual study varied considerably, ranging from 9.5 to 38.6%. Thrombosis could be on either arterial or venous site and appeared to be more common among patients who were newly diagnosed with PV than ET and PMF. The pathogenesis of acquired thrombophilic state in these patients is probably multifactorial in nature. Two main mechanisms have been proposed. One involves abnormalities of platelets, leukocytes, and red blood cells arising from the clonal hematopoietic cell proliferation. These abnormal cells interact and activate coagulation pathway more often than normal cells, leading to chronic activation of the coagulation cascade. Another postulated mechanism involves the chronic inflammatory state of MPN as studies have demonstrated that inflammatory cytokines can cross-activate coagulation factors and inhibit fibrinolytic pathway. In addition, those cytokines and reactive oxygen species are known to post deleterious effect on vascular endothelial cells, resulting in vascular injury. Both would serve as the fundamental factors for increased clotting tendency [39–41].

On the other hand, a high prevalence of hemorrhage at diagnosis was also observed in patients with MPN, although lower than the prevalence of thrombosis. The pathogenesis of hemorrhagic complications among patients with MPN is also probably multifactorial but it is believed that acquired von Willebrand disease from excessive binding of von Willebrand factor with the abnormal platelets and increased von Willebrand factor proteolysis is the most likely major player [42, 43]. In fact, the pattern of bleeding among patients with MPN, including gastrointestinal, mucosal, and cutaneous bleeding, is quite similar to von Willebrand disease [44]. Other possible contributing factors include thrombocytopenia from bone marrow failure associated with advance disease and secondary hemostatic defects from liver impairment due to liver fibrosis and extramedullary hematopoiesis associated with PMF [42].

The high frequency of both thrombotic and hemorrhagic events among patients with MPN demonstrated by this study has some clinical implications. First, both thrombosis and bleeding are common initial manifestations of MPN. Therefore, investigations for MPN may be warranted for patients who present with unexplained thrombosis or abnormal bleeding. Second, patients with MPN should be considered as those at higher risk of thrombotic complication and, therefore, prophylaxis with anti-platelet and/or anti-coagulation may provide benefit. Nonetheless, these patients are also at a higher risk of hemorrhagic complication and the potential benefit of thrombotic prophylaxis needs to be balanced with the bleeding risk especially in patient with extreme thrombocytosis. Further studies are still needed before the final recommendations can be made.
There are some limitations in this study. First, it is a meta-analysis of descriptive studies that reported the prevalence of thrombosis and bleeding among patients with MPN. There were no subjects without MPN to serve as controls and, therefore, this study could not provide the information on the magnitude of the risk relative to general population. Second, between-study heterogeneity was high in most analyses which was probably due to the fact that the included studies were conducted over the time span of the past three decades and the diagnostic criteria for each MPN subtype have evolved during that time. To illustrate, based on the 2001 World Health Organization (WHO) classification of MPNs, hemoglobin level > 18.5 g/dL in man and > 16.5 g/dL in woman were the criteria for the diagnosis of PV and one of criteria for the diagnosis of ET was platelet count ≥600 x 10^9/L [45]. However, the cut-offs for PV and ET in the 2016 WHO classification of MPNs were lowered to the hemoglobin levels of > 16.5 g/dL in man and > 16 g/dL in woman and platelet count of ≥450 x 10^9/L, respectively [2]. Therefore, some cases of PV and ET could have been missed by the previous classification criteria. As a result, it is likely that the characteristics of the diseases are different between the older and newer studies, even though they are labeled with the same name. It is also likely that the differences in the technology used to identify thrombosis and bleeding among these patients during the period would have affected the prevalence.

Conclusions
Thrombosis and bleeding are common initial manifestations of MPN. Investigations for MPN should be considered for patients who present with unexplained thrombosis or abnormal bleeding.

Acknowledgements
Not applicable.

Funding
This was an unfunded study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
All authors designed the study. TR1 and WO manually reviewed the potential articles, selected the included studies, collected the data, and drafted the manuscript. P.U. performed the statistical analyses. NS, TR2, and PU made critical revisions to the manuscript. TR1 and WO revised the final manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The need for ethics approval by an institutional board review was waived as this study does not directly involve human subjects.

Consent for publication
Not applicable because this study does not directly involve human subjects.

Competing interests
The authors declare that they have no competing interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Medicine, Phranangklao Hospital, Nonthaburi 11000, Thailand.
2Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok 10700, Thailand.
3Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

Received: 1 October 2018 Accepted: 19 February 2019
Published online: 28 February 2019

References
1. Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168–81.
2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
3. Kc D, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017;96(10):1595–604.
4. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507–13 quiz 615.
5. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program. 2012;2012:2571–81.
6. Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malignancy Rep. 2017;12(5):389–96.
7. Fenaux P, Simon M, Cauiller MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66(3):549–56.
8. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia: a retrospective study of 103 patients. Cancer. 1991;67(1):2926–30.
9. Bessis C, Cervantes F, Pereira A, Florena L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13(2):150–4.
10. Manoharan A, Gemmell R, Brighton T, Dunkeley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol. 1999;105(3):618–25.
11. Jensen MK, de Nully BP, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65(2):132–9.

12. Passamonti F, Rusuardi L, Ezzario M, Barile C, Ileresy C, Orlandi E, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000;85(10):1011–8.

13. Chir S, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005;165(22):2651–8.

14. Marchioli R, Finazzi G, Landolfi R, Kuss O, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.

15. Cervantes F, Alvarez-Larran A, Alegre-Elordi E, Granell M, Domingo A, Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 2006;20(1):55–60.

16. Wolsky AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159–66.

17. Carobbio A, Finazzi G, Guerin V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310–3.

18. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840–6.

19. Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, et al. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to Jak2 mutation. Thromb Haemost. 2009;101(3):547–51.

20. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778–82.

21. Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95(5):1788–91.

22. Paladini F, Polverelli N, Catani L, Ottaviani E, Baccarini M, Vannelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia a retrospective study. Ann Hematol. 2011;90(8):893–8.

23. Buxhofer-Ausch V, Gisslinger H, Theile J, Gisslinger B, Kvasnicka HM, Mullauer L, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients. Ann Hematol. 2010;91(4):571–9.

24. Finazzi G, Carobbio A, Theile J, Passamonti F, Runzi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(7):669–72.

25. Angona A, Alvarez-Larran A, Melo B, Martinez-Aviles L, Garcia-Pallarols F, Longaron R, et al. Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients. Med Clin (Barc). 2015;144(6):247–53.

26. Emblov A, Lindskog E, Hasselbalch H, Hentzy D, Bak M, Tett J, et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 2015;26(5):344–7.

27. Lim Y, Lee JD, Kim SH, Kim JW, Kim YJ, Lee KW, et al. Prediction of thrombotic and hemorrhagic episodes during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res. 2015;135(5):846–51.

28. Duangnapasatit B, Rattanathammethe T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, et al. Clinical manifestations and risk factors for complications of Philadelphia chromosome-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev. 2015;16(12):5013–8.

29. Kailie A, Kirschner M, Wolf D, Mainz C, Hanel M, Gattemann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPNs). Analysis from the German SAl-MLP-register. J Hematol Oncol. 2016;9:18.

30. Cenciczi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7(12):662.

31. Abdulkarim K, Samuelsson J, Johannsson P, Andrasonn B. Risk factors for vascular complications and treatment patterns at diagnosis of 2889 PV and ET patients: real-world data from the Swedish MPN registry. Eur J Haematol. 2017;98(5):577–83.

32. Soyer N, Haznederoğlu IC, Comert M, Cekdemir D, Yilmaz M, Unal A, et al. Multicenter retrospective analysis of Turkish patients with chronic myeloproliferative neoplasms. Turk J Haematol. 2017;34(1):27–33.

33. Bertozzi I, Bogoni G, Biagetti G, Duner E, Lombardi AM, Fabris F, et al. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol. 2017;96(8):1297–302.

34. Zhou D, Chen W, Cheng H, Qiao JL, Zhu LL, Li ZY, et al. Clinico-hematological profile and thrombotic/hemorrhagic events in 150 Chinese patients with essential thrombocythemia. Leuk Res. 2018;69:1–6.

35. Hintermair S, Zwickl-Traderl E, Pecherstorfer M, Singer J. Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the janus kinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015. Oncotarget. 2018;9(9):8450–62.

36. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.

37. Mathes T, Reus O. A comparison of methods for meta-analysis of a small number of studies with binary outcomes. Res Synth Methods. 2018;9:1–16.

38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

39. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie. 2010;30(1):4–9.

40. Vaquez-Garza E, Jerez-Sanchez C, Navarete A, Joya-Harrison J, Rodriguez D. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolys. 2017;44(3):377–85.

41. Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348–58.

42. Appelmann I, Kreher S, Parmentier S, Wolf HH, Bispeng G, Kirschner M, et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the hemostasis working Party of the German Society of hematology and medical oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol. 2016;95(5):707–18.

43. Buddle U, Dent JA, Berkowitz SD, Ruggeri ZM. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolys. 2017;44(3):377–85.

44. Keesler DA, Flood VH. Current issues in diagnosis and treatment of von Willebrand disease. Rev Prat Thromb Haemost. 2018;68(1):123–7.

45. Vardiman JW. Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. Semin Diagn Pathol. 2003;20(3):154–79.